CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $10.52B, above the global median of $1.18B
- PositionProfit margin is 38.2%, higher than 95% of its Biotechnology peers (median 8.4%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
70.72BCNY10.52B · vs all stocks (USD)
Trailing P/E
102.60xvs Biotechnology peers
Revenue (TTM)
3.38BCNY502.83M · vs all stocks (USD)
Profit Margin
38.20%vs Biotechnology peers
Beta
0.4540xvs all stocks
52-Week Change
59.00%vs all stocks
Market Capitalization
70.72BCNY10.52B · vs all stocks (USD)
Enterprise Value
71.91BCNY10.69B · vs all stocks (USD)
Trailing P/E
102.60xvs Biotechnology peers
Forward P/E
96.86xvs Biotechnology peers
Price to Sales (TTM)
22.23xvs Biotechnology peers
Price to Book (MRQ)
19.20xvs Biotechnology peers
Enterprise to Revenue
21.27xvs Biotechnology peers
Enterprise to EBITDA
120.11xvs Biotechnology peers
Profit Margin
38.20%vs Biotechnology peers
Operating Margin
-3.36%vs Biotechnology peers
Return on Assets (TTM)
3.38%vs Biotechnology peers
Return on Equity (TTM)
45.33%vs Biotechnology peers
Revenue (TTM)
3.38BCNY502.83M · vs all stocks (USD)
Revenue per Share (TTM)
6.11CNYUpdated Aug 21, 2026Quarterly Revenue Growth
24.80%vs Biotechnology peers
Gross Profit (TTM)
2.94BCNY436.74M · vs all stocks (USD)
EBITDA (TTM)
454.98MCNY67.66M · vs all stocks (USD)
Net Income (TTM)
1.29BCNY192.10M · vs all stocks (USD)
Operating Cash Flow (TTM)
252.59MCNY37.56M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
933.28MCNY138.79M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.24BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
425.50MCNYFY2025 · Dec 31, 2025Gross Profit
2.82BCNYFY2025 · Dec 31, 2025Operating Income
156.35MCNY23.25M · vs all stocks (USD)
Pre-tax Income
710.40MCNYFY2025 · Dec 31, 2025Income Tax Expense
749.00KCNYFY2025 · Dec 31, 2025Net Income
709.65MCNYFY2025 · Dec 31, 2025EBIT
780.57MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
454.98MCNYFY2025 · Dec 31, 2025Research & Development
1.22BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.47BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.59MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
70.17MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.29CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.29CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
549.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
549.76MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
233.97MCNYFY2025 · Dec 31, 2025Free Cash Flow
36.34MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.15BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
710.40MCNYFY2025 · Dec 31, 2025Stock-based Compensation
33.90MCNYFY2025 · Dec 31, 2025Other Non-cash Items
66.24MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-568.59MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.97MCNYFY2025 · Dec 31, 2025Capital Expenditures
-197.64MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-240.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
-13.10MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.16BCNYFY2025 · Dec 31, 2025Sale of Investments
2.16BCNYFY2025 · Dec 31, 2025Other Investing Activity
610.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-204.80MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.03BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.12BCNYFY2025 · Dec 31, 2025Other Financing Charges
-40.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
697.52MCNYFY2025 · Dec 31, 2025Shares Outstanding
563.71MSharesUpdated Aug 21, 2026Float Shares
347.60MSharesUpdated Aug 21, 2026% Held by Insiders
56.90%vs all stocks
% Held by Institutions
13.54%vs all stocks
Total Cash (MRQ)
2.75BCNY408.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.85CNYUpdated Aug 21, 2026Total Debt (MRQ)
2.09BCNY311.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5331xvs Biotechnology peers
Current Ratio (MRQ)
1.58xvs Biotechnology peers
Book Value per Share (MRQ)
6.95CNYUpdated Aug 21, 2026Total Assets
7.25BCNY1.08B · vs all stocks (USD)
Total Current Assets
3.98BCNYFY2025 · Dec 31, 2025Total Liabilities
3.64BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.27BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
846.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.79BCNYFY2025 · Dec 31, 2025Cash
1.15BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.15BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.22BCNYFY2025 · Dec 31, 2025Accounts Receivable
422.77MCNYFY2025 · Dec 31, 2025Inventory
661.49MCNYFY2025 · Dec 31, 2025Accounts Payable
285.85MCNYFY2025 · Dec 31, 2025Short-term Debt
1.45BCNYFY2025 · Dec 31, 2025Other Current Liabilities
38.67MCNYFY2025 · Dec 31, 2025Long-term Debt
751.90MCNYFY2025 · Dec 31, 2025Common Stock (Book)
563.71MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.61BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.61BCNY536.67M · vs all stocks (USD)
Treasury Stock
237.19MCNYFY2025 · Dec 31, 202552-Week Low
75.03CNYUpdated Aug 21, 202652-Week High
157.80CNYUpdated Aug 21, 202652-Week Change
59.00%vs all stocks
Beta
0.4540xvs all stocks
50-Day MA
124.24CNYUpdated Aug 21, 2026200-Day MA
111.41CNYUpdated Aug 21, 2026Avg 10-Day Volume
10.25MSharesUpdated Aug 21, 2026Avg 30-Day Volume
9.12MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.30CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 38.2%, higher than 95% of its Biotechnology peers (median 8.4%)Significant
Profit margin: 0.38Industry median: 0.08Industry P95: 0.34Peers compared: 24.00
Return on equity is 45.3%, higher than 95% of its Biotechnology peers (median 6.3%)Significant
Return on equity: 0.45Industry median: 0.06Industry P95: 0.40Peers compared: 24.00
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 192,103,777.866Operating Cash Flow (USD, TTM): 37,561,918.919
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.82
Altman Z-Score 11.96: safe zoneNotable
Altman Z-Score: 11.96
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $10.52B, above the global median of $1.18BNotable
Market cap (USD): 10,516,960,124.753Global Median: 1,179,398,897.704
Levered free cash flow is $138.79M, above the global median of $19.19MNotable
Levered free cash flow (USD): 138,788,525.637Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Krystal Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
InnoCare Pharma Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag
Lontium Semiconductor Corp.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag
Anhui XDLK Microsystems Co., Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag